Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CHLORZOXAZONE vs CYCLOSET
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.
Cycloset (bromocriptine mesylate) is a dopamine D2 receptor agonist. It improves glycemic control in type 2 diabetes by resetting hypothalamic circadian rhythms, thereby reducing hepatic glucose production and increasing insulin sensitivity. It also suppresses the release of very low-density lipoprotein from the liver.
Adjunct for relief of acute painful musculoskeletal conditions associated with muscle spasm
FDA-approved: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.,Off-label: Parkinson's disease, hyperprolactinemia, acromegaly, neuroleptic malignant syndrome.
250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.
1.6 mg to 2.4 mg administered orally once daily at bedtime. Titrate by 0.8 mg every 2 weeks based on glycemic response and tolerability.
Terminal elimination half-life approximately 1–2 hours; clinically relevant for muscle relaxant effect duration.
Terminal elimination half-life is 4–6 hours in patients with normal renal function; clinically, steady-state is reached within 24 hours.
Hepatic, primarily via CYP2E1, also CYP1A2 and CYP3A4
Primarily hepatic via cytochrome P450 3A4 (CYP3A4). Inactive metabolites are excreted mainly in feces (80%) and urine (2-10% unchanged).
Primarily hepatic metabolism followed by renal excretion of metabolites; <1% excreted unchanged in urine; minor biliary/fecal elimination.
Renal: ~90% (30% unchanged, rest as inactive metabolites); fecal: ~10%.
Approximately 90–95% bound, primarily to albumin.
~20–30% bound, primarily to albumin.
0.46–0.64 L/kg; indicates distribution into total body water.
0.5–1.0 L/kg, indicating moderate distribution into tissues.
Oral: nearly complete; rapidly absorbed with extensive first-pass metabolism; systemic bioavailability approximately 30–50% due to first-pass effect.
Oral: ~65–75% due to first-pass metabolism.
No specific guidelines; use with caution in severe renal impairment (GFR <30 m L/min) due to potential accumulation of active metabolite.
Contraindicated in patients with e GFR <30 m L/min/1.73 m2. For e GFR 30-50 m L/min/1.73 m2: maximum dose 0.8 mg daily.
Contraindicated in hepatic impairment; avoid use in Child-Pugh class B or C due to risk of hepatotoxicity.
No dose adjustment required for mild hepatic impairment (Child-Pugh class A). Not recommended in moderate to severe hepatic impairment (Child-Pugh class B or C) due to lack of data.
Not established; safety and efficacy not studied in pediatric patients.
Not approved for pediatric patients. Safety and efficacy in patients <18 years have not been established.
Initiate at lower end of dosing range (250 mg 3-4 times daily); monitor for CNS effects (dizziness, drowsiness) and liver function.
Start at 0.8 mg once daily; titrate slowly due to increased risk of orthostatic hypotension and hypoglycemia. Consider renal function and comorbidities.
None
None.
May cause drowsiness, dizziness, or impaired coordination. Caution in patients with hepatic impairment. Discontinue if hypersensitivity reactions occur. Avoid concurrent use with alcohol or other CNS depressants.
Risk of hypotension, especially at initiation of therapy; monitor blood pressure.,May cause somnolence and dizziness; advise patients not to drive or operate machinery until effects are known.,Use with caution in patients with cardiovascular disease, especially those with angina or recent myocardial infarction.,May exacerbate psychotic disorders; use caution in patients with a history of psychosis.,Fibrotic complications (pulmonary, pericardial, retroperitoneal fibrosis) have been reported with ergot-derived dopamine agonists; monitor for symptoms.,Discontinue if signs of cardiac valvulopathy occur.
Hypersensitivity to chlorzoxazone or any component of the formulation; impaired hepatic function
Hypersensitivity to bromocriptine or any component of the formulation.,Concomitant use with CYP3A4 inducers (e.g., rifampin, anticonvulsants) or inhibitors (e.g., azole antifungals, macrolide antibiotics).,Severe ischemic heart disease or peripheral vascular disorders.,Syncopal migraine or history of myocardial infarction with residual arrhythmias.,Uncontrolled hypertension.,Lactation: inhibits lactation, do not use in women with pregnancy or nursing unless essential.
No significant food interactions. Take with or without food. Grapefruit juice may increase drug levels; avoid large quantities.
Avoid alcohol and alcohol-containing products. No specific food interactions; take with or without food. Maintain adequate hydration.
Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if clearly needed and after weighing risks vs. benefits. Avoid during first trimester unless necessary.
First trimester: insufficient human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: no known fetal risks; drug may cause maternal hypoglycemia which can affect fetus.
Not recommended during breastfeeding due to potential for sedation in the infant. No M/P ratio data available.
Not recommended; no data on excretion in human milk. M/P ratio unknown.
No dosage adjustment specific to pregnancy is required based on pharmacokinetic data; however, clinical response should be monitored.
Monitor glucose closely; dose adjustments may be needed due to altered pharmacokinetics in pregnancy (increased clearance). Start at lowest effective dose; titrate based on glycemic response.
Chlorzoxazone is a centrally acting muscle relaxant used for acute musculoskeletal pain. Onset of action is within 1 hour; peak effect at 1-2 hours. Monitor for hepatotoxicity, especially with prolonged use or high doses. Can cause drowsiness and impair motor skills; avoid concurrent use with alcohol or other CNS depressants. Tablets may be crushed for patients with swallowing difficulties.
Monitor for hypoglycemia, especially in elderly patients or those with renal impairment. Cycloserine may accumulate in renal insufficiency; dose reduction is necessary if Cr Cl < 50 m L/min. Watch for neuropsychiatric effects (seizures, psychosis, depression) and discontinue if severe. Pyridoxine 50-100 mg daily is recommended to reduce neurotoxicity. Avoid alcohol due to increased seizure risk.
Take exactly as prescribed; do not increase dose or frequency.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Avoid alcohol and other CNS depressants while taking this medication.,Report signs of liver problems: dark urine, yellowing of eyes/skin, persistent nausea, abdominal pain.,Do not suddenly stop taking if used long-term; taper under medical supervision to avoid withdrawal.
Take exactly as prescribed; do not miss doses or double up.,Report any signs of rash, confusion, dizziness, or unusual behavior immediately.,Avoid alcohol completely while on this medication.,If you have kidney problems, your dose may need adjustment.,Take pyridoxine (vitamin B6) as directed to lower risk of side effects.,Do not drive or operate heavy machinery if you feel drowsy or dizzy.,Complete the full course of therapy even if you feel better.
"Lumacaftor is a strong inducer of cytochrome P450 (CYP) 3A4 and other drug-metabolizing enzymes, including CYP2E1. Chlorzoxazone is primarily metabolized by CYP2E1 to its inactive metabolite. Concomitant use increases CYP2E1 activity, leading to accelerated chlorzoxazone clearance and reduced systemic exposure, potentially diminishing its therapeutic effect as a muscle relaxant."
"Chlorzoxazone, a centrally acting muscle relaxant, inhibits the metabolism of diltiazem, a calcium channel blocker, via competitive inhibition of CYP3A4. This leads to increased plasma concentrations of diltiazem, potentially causing enhanced negative chronotropic and vasodilatory effects, resulting in bradycardia, hypotension, or atrioventricular block. Patients may experience dizziness, syncope, or exacerbate heart failure symptoms."
"Butalbital, a barbiturate, induces hepatic cytochrome P450 enzymes (particularly CYP2E1), accelerating the metabolism of chlorzoxazone, a centrally acting muscle relaxant primarily metabolized by CYP2E1. This results in reduced plasma concentrations of chlorzoxazone, leading to diminished therapeutic efficacy and potential loss of symptom control. Clinically, patients may experience inadequate muscle relaxation, requiring dose adjustments or alternative therapy."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CHLORZOXAZONE vs CYCLOSET, answered by our medical review team.
CHLORZOXAZONE is a Skeletal Muscle Relaxant that works by Chlorzoxazone acts centrally on the spinal cord and subcortical areas of the brain to inhibit multisynaptic reflex arcs involved in producing and maintaining muscle spasm. It may also have some sedative effects.. CYCLOSET is a Dopamine Agonist / Antidiabetic that works by Cycloset (bromocriptine mesylate) is a dopamine D2 receptor agonist. It improves glycemic control in type 2 diabetes by resetting hypothalamic circadian rhythms, thereby reducing hepatic glucose production and increasing insulin sensitivity. It also suppresses the release of very low-density lipoprotein from the liver.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CHLORZOXAZONE and CYCLOSET depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CHLORZOXAZONE is: 250-500 mg orally 3-4 times daily, maximum 750 mg 4 times daily.. The standard adult dose of CYCLOSET is: 1.6 mg to 2.4 mg administered orally once daily at bedtime. Titrate by 0.8 mg every 2 weeks based on glycemic response and tolerability.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CHLORZOXAZONE and CYCLOSET in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CHLORZOXAZONE is classified as Category C. Teratogenic risk in humans is not well-studied. No major teratogenic effects have been reported in animal studies. However, as with all medications, use during pregnancy only if cl. CYCLOSET is classified as Category C. First trimester: insufficient human data; animal studies show no teratogenicity at clinically relevant doses. Second and third trimesters: no known fetal risks; drug may cause mate. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.